Brachytherapy: Procedure, Types, and Side Effects — Cost, Top Hospitals & Success Rates | MyMedicPlus

Brachytherapy (from the Greek brachy — short distance) is a form of radiotherapy in which radioactive sources are placed inside or immediately adjacent to the tumour, delivering a highly localised radiation dose with rapid dose fall-off to surrounding healthy tissues. Unlike external beam radiotherapy (EBRT), where a linear accelerator directs radiation from outside the body, brachytherapy places the radiation source at the target site — maximising tumour dose while minimising exposure to adjacent organs at risk.

The principle of brachytherapy dates to Henri Becquerel's and Pierre Curie's discovery of radioactivity at the turn of the 20th century, with early radium applications in the cervix reported by Abbe and Forsell before 1910. Modern brachytherapy bears little resemblance to these early procedures: contemporary practice uses computer-optimised treatment planning, image-guided applicator placement (CT, MRI, and transrectal ultrasound), and computerised remote afterloading machines (Nucletron Oncentra, Eckert and Ziegler) that eliminate radiation exposure to operators and staff.

Brachytherapy is classified by dose rate: low dose rate (LDR) delivers continuous radiation over days to months from permanently implanted or temporarily placed sources; high dose rate (HDR) delivers a high dose over minutes via a remote afterloading machine using Iridium-192 (Ir-192), allowing outpatient treatment; and pulsed dose rate (PDR) delivers hourly pulses mimicking LDR radiobiology over 24 hours using the PARIS technique. It is further classified by anatomical technique: intracavitary (applicators placed in body cavities — uterus, vagina, oesophagus, bronchus, rectum), interstitial (needles/catheters implanted directly into tissue — prostate, breast, head and neck), and surface/mould (applicators placed on skin or mucosal surfaces).

Brachytherapy is used as definitive monotherapy (LDR seed implant for low-risk prostate cancer), as a focal boost within multimodality treatment (HDR brachytherapy boost for locally advanced cervical cancer after EBRT), or as accelerated partial breast irradiation (APBI) for early-stage breast cancer. Internationally, it is considered the standard of care for cervical cancer by multiple guidelines (ESTRO, GEC-ESTRO, NCCN, ESMO).

Brachytherapy is used across a range of cancer types, either as primary treatment, boost, or salvage:

• Prostate cancer (LDR seed implant): Permanent LDR prostate brachytherapy using Iodine-125 (I-125, half-life 59.4 days, mean energy 27.4 keV) or Palladium-103 (Pd-103, half-life 17 days, preferred for higher-grade disease) seeds is a definitive curative treatment for low- and favourable-intermediate-risk prostate cancer. Seeds are implanted transperineally under transrectal ultrasound (TRUS) guidance under spinal or general anaesthesia as a day case. The ongoing radiation dose from permanently implanted seeds delivers approximately 145 Gy (I-125) or 125 Gy (Pd-103) to the prostate over approximately 2 months (I-125) before decaying to near-zero activity.
• Prostate cancer (HDR boost): For intermediate- and high-risk prostate cancer, HDR brachytherapy combined with EBRT provides dose escalation to the prostate whilst limiting rectal and bladder exposure. Typical HDR boost fractionation: 15 Gy single fraction or 10.5 Gy in 2 fractions combined with 45–46 Gy EBRT to the pelvis. ASCENDE-RT trial demonstrated superior biochemical progression-free survival for LDR boost versus EBRT dose-escalation alone.
• Cervical cancer (intracavitary HDR): Brachytherapy is essential in the definitive treatment of FIGO Stage IB2–IVA cervical cancer following external beam chemoradiation (cisplatin concurrent). GEC-ESTRO/EMBRACE image-guided adaptive brachytherapy (IGABT) using CT/MRI-compatible applicators (Fletcher-Williamson tandem and ovoid, Vienna ring, tandem-and-ring) delivers HDR fractions (typically 5.5–6 Gy per fraction, 4–5 fractions) to achieve a total EQD2 (equivalent dose in 2 Gy fractions) of ≥85 Gy to the high-risk clinical target volume (HRCTV). The EMBRACE I trial (1,400 patients, 23 centres) reported 91% local control at 3 years for Stage IB–IIB disease with IGABT.
• Endometrial cancer: Vaginal vault brachytherapy (HDR, typically 5.5–6 Gy to the upper 3–5 cm of vaginal vault, 3 fractions) is standard adjuvant treatment following surgery for intermediate-risk endometrial cancer, reducing vaginal vault recurrence rates to less than 2% (PORTEC-1 and PORTEC-2 trials).
• Breast cancer (APBI): Accelerated partial breast irradiation (APBI) delivers targeted radiotherapy to the tumour bed only (rather than whole breast) over 4–5 days rather than 3–6 weeks. Techniques include interstitial catheters (APBI), intracavitary balloon devices (MammoSite), and intraoperative radiotherapy (IORT) using Intrabeam (30 kV x-rays) or ELIOT (electron beam). The TARGIT-A international RCT demonstrated 5-year local breast cancer recurrence rates of 3.3% (TARGIT) vs. 1.3% (whole breast EBRT) in pre-selected low-risk patients, with equivalent overall survival and better cosmesis.
• Head and neck cancers: Interstitial brachytherapy of the tongue, floor of mouth, soft palate, and lip provides dose escalation for early-stage oral cavity and oropharyngeal cancers. PDR brachytherapy using the PARIS dosimetry system is the traditional technique; HDR interstitial with plastic tube implants is increasingly used. Reirradiation brachytherapy is used for localised recurrences in previously irradiated fields where further EBRT is not feasible.
• Other sites: Oesophageal brachytherapy (intraluminal HDR for palliation or definitive treatment); bile duct (biliary) brachytherapy; rectal/anal canal brachytherapy; skin cancer (HDR surface applicators or LDR mould therapy); and vaginal brachytherapy for primary vaginal cancer.

Patient selection for brachytherapy depends on tumour characteristics, anatomical suitability, and prior treatment history:

• Prostate LDR seed eligibility: Optimal candidates have low-risk (PSA less than 10 ng/mL, Gleason Grade Group 1, Stage T1c–T2a) or favourable intermediate-risk prostate cancer (one intermediate-risk factor, PSA 10–20 ng/mL or GGG 2, less than 50% positive biopsy cores). Prostate gland volume should ideally be less than 50 cc (larger glands may cause pubic arch interference, assessable on TRUS or MRI). Prior TURP (transurethral resection of the prostate) is a relative contraindication due to increased urinary toxicity risk from seed migration into resection defects. IPSS (International Prostate Symptom Score) less than 15 is preferred. Patients receiving neoadjuvant androgen deprivation therapy (ADT) for 3 months pre-implant can reduce gland volume to facilitate seed placement in initially borderline cases.
• Cervical cancer brachytherapy eligibility: Standard indication is FIGO Stage IB2–IVA cervical cancer following completion of concurrent chemoradiation (45–50 Gy EBRT + weekly cisplatin 40 mg/m²). MRI before and after EBRT is essential for IGABT planning to define the HRCTV and organs at risk. Patients must be able to tolerate applicator insertion under regional or general anaesthesia. Uterine perforation or obliterated vaginal cavity from disease may limit intracavitary access, requiring interstitial component or template insertion.
• APBI / breast brachytherapy eligibility: ASTRO consensus guidelines (Suitable category) specify: age ≥50 years, invasive ductal carcinoma, pT1–pT2 (up to 3 cm), pN0 (sentinel node negative), negative margins (≥2 mm), no extensive DCIS. Unfavourable features include lobular histology, BRCA mutations, extensive DCIS, and lymphovascular invasion. TARGIT-A IORT eligibility: risk score ≥8 on the Preoperative Risk Score (avoiding EBRT in selected patients with pathological information available at the time of intraoperative RT).
• General medical eligibility: All brachytherapy procedures require adequate anaesthetic fitness for the implant procedure. HDR brachytherapy is typically delivered as a day case or with 1–2 day hospital admission, making it accessible to frail patients who cannot tolerate prolonged hospitalisation associated with LDR temporary implants.

Low dose rate (LDR) brachytherapy:

• Permanent prostate seed implant: Pre-planned or real-time TRUS-guided implantation of 60–120 I-125 titanium seed capsules (4.5 mm x 0.8 mm) transperineally through a perineal grid template under GA/spinal anaesthesia. Seeds are distributed throughout the prostate to achieve a V100 (volume receiving 100% of prescribed dose) of ≥90% of the prostate. A post-implant Day 30 CT-based dosimetry assessment (D90 — dose covering 90% of prostate volume) confirms adequacy of implant; D90 ≥140 Gy for I-125 is the quality standard.
• Temporary LDR implant: Historically, iridium wire implants for breast, tongue, and soft palate cancers using the PARIS dosimetry system. Now largely replaced by PDR and HDR techniques at most centres.

High dose rate (HDR) brachytherapy:

• Remote afterloading: An HDR remote afterloading machine (Nucletron Flexitron, Eckert and Ziegler) contains a single high-activity Ir-192 source (370 GBq; 10 Ci; 0.3 mm x 3.5 mm). Following computer-optimised treatment planning, the source is pneumatically driven through flexible transfer catheters to pre-calculated dwell positions for precise fractions of a second at each position, delivering the prescribed dose over 5–15 minutes per fraction. Staff leave the treatment room during treatment; the procedure is performed in a lead-shielded room. No radiation remains in the patient between or after fractions.
• HDR prostate boost: 15 Gy single fraction or 10.5 Gy × 2 fractions (separated by 1 week) delivered via transperineally placed catheters under TRUS/MRI guidance, combined with 46 Gy EBRT to the prostate and seminal vesicles. MRI-guided HDR prostate brachytherapy in an MRI suite allows real-time tumour visualisation during implantation.
• HDR cervical cancer (intracavitary IC-BT): Following EBRT completion, 4–5 HDR fractions (5–6 Gy per fraction) are delivered via ring or tandem-and-ovoid/tandem-and-ring applicators placed under anaesthesia. MRI-guided applicator imaging between each fraction enables adaptive plan optimisation to account for tumour response and daily anatomy variations — the core of the GEC-ESTRO EMBRACE IGABT paradigm. Total treatment typically spans 1–2 weeks.
• Interstitial brachytherapy for breast APBI: Multiple parallel catheters (10–20) are implanted through the breast in a two-plane geometry encompassing the lumpectomy cavity (identified by surgical clips). HDR fractions of 3.4 Gy twice daily (separated by ≥6 hours) for 5 days (10 fractions, 34 Gy total) or 4 Gy twice daily for 4 days (GEC-ESTRO protocol) deliver APBI. The GEC-ESTRO randomised trial demonstrated equivalent 5-year local control between interstitial APBI and whole breast EBRT in suitable patients.

Pulsed dose rate (PDR) brachytherapy: Uses the same Ir-192 HDR remote afterloading source but delivers the dose in repeated hourly pulses (typically 0.5–1 Gy per pulse for 10–20 minutes per hour) over 24–48 hours to mimic continuous LDR dose rate biology. The PARIS dosimetry system (developed for head and neck interstitial brachytherapy) specifies geometric catheter arrangement. PDR is used primarily for oral cavity and oropharyngeal tumours, and for some breast and gynaecological applications at European centres.

Brachytherapy offers several radiobiological and logistical advantages over external beam radiotherapy in appropriate indications:

• Superior dose localisation and rapid dose fall-off: Radiation dose from brachytherapy sources follows the inverse square law — dose decreases with the square of the distance from the source. This means tumour tissue 5 mm from the source receives 4 times more dose than tissue 10 mm away, enabling very high tumour doses whilst sharply limiting exposure of adjacent rectum, bladder, small bowel, and neurovascular structures compared with EBRT techniques alone.
• Equivalent or superior biochemical control vs. EBRT (prostate): The RAVES (Radiation Therapy Oncology Group) randomised trial (Australia and New Zealand) demonstrated equivalent 5-year biochemical failure-free survival between LDR brachytherapy boost plus EBRT and EBRT dose-escalation alone (46 Gy EBRT), with the brachytherapy arm showing significantly lower Grade 2+ rectal toxicity. The ASCENDE-RT RCT demonstrated superior biochemical control for LDR boost vs. EBRT boost at 9-year follow-up (83% vs. 75% biochemical failure-free survival; P=0.001), establishing LDR boost as the standard for intermediate-/high-risk disease at experienced centres.
• Improved local control in cervical cancer (IGABT): The EMBRACE I prospective cohort study (1,416 patients) demonstrated that MRI-guided adaptive brachytherapy for locally advanced cervical cancer achieves 3-year local control of 91.6% for Stage IB–IIB and 78.7% for Stage III–IVA disease, with a pelvic-specific complication-free rate of 78% — substantially better than historical outcomes with point-A-based conventional brachytherapy.
• Shorter treatment time (APBI): Conventional whole breast radiotherapy requires 3–6 weeks of daily hospital visits. APBI via interstitial brachytherapy or intraoperative radiotherapy (IORT) completes treatment in 4–5 days or even a single intraoperative fraction, reducing patient burden, improving quality of life, and enabling access to radiotherapy for patients who cannot commit to prolonged courses.
• Outpatient/day-case delivery (HDR): HDR brachytherapy is predominantly delivered on an outpatient or day-case basis. Patients with prostate HDR boost attend for two day-case admissions; cervical cancer HDR fractions require 4–5 short hospitalisations of 1–2 days. This is particularly advantageous for elderly or frail patients and those travelling from distant locations.
• Organ function preservation: In early-stage oral cavity cancer, interstitial brachytherapy can achieve local control equivalent to surgery whilst preserving speech and swallowing function, avoiding the anatomical and functional deficits of partial glossectomy.

The toxicity profile of brachytherapy is site-specific and generally compares favourably with EBRT for equivalent tumour control:

• Prostate LDR seed implant — urinary toxicity: Urinary symptoms (frequency, urgency, dysuria, nocturia, weak stream) are common in the first 3–6 months post-implant, reflecting oedema and local radiation effect on the urethra and bladder neck. IPSS scores typically peak at 1–4 months and return to baseline by 12 months in most patients. Acute urinary retention requiring catheterisation occurs in approximately 5–15%. Alpha-blockers (tamsulosin 0.4 mg) prescribed for 6–12 months post-implant significantly reduce urinary LUTS.
• Prostate LDR/HDR — erectile dysfunction (ED): ED following prostate brachytherapy monotherapy is lower than post-radical prostatectomy but higher than watchful waiting. Reported rates of preserved erections sufficient for intercourse at 5 years post-LDR brachytherapy monotherapy range from 60–80% in prospective series, superior to approximately 50% for dose-escalated EBRT. Phosphodiesterase type 5 inhibitors (sildenafil, tadalafil) are effective for radiation-induced ED.
• Prostate brachytherapy — rectal toxicity: Grade 2+ rectal toxicity (proctitis, rectal bleeding, fistula) is the principal serious late complication. Rates of Grade 2+ rectal toxicity with LDR monotherapy are approximately 5–10% at 5 years; HDR boost plus EBRT RAVES trial: Grade 2+ rectal toxicity 12% (HDR arm) vs. 22% (EBRT dose-escalation arm) at 5 years, confirming lower rectal toxicity with brachytherapy-based dose escalation. Rectobrachytherapy fistula is rare (<1%) but serious.
• Cervical cancer brachytherapy — gastrointestinal toxicity: Grade 3+ late GI toxicity (haematochezia, bowel obstruction, fistula) occurs in approximately 5–7% of patients in the EMBRACE I series, with grade 2+ rectal bleeding in approximately 10–12%. Risk is reduced by IGABT dose constraints limiting rectal D2cc (dose to the highest-dose 2 cc volume) to less than 65 Gy EQD2. Fistula (rectovaginal, vesicovaginal) occurs in less than 2–3% of patients with IGABT vs. historically 5–10% with conventional point-A-based brachytherapy.
• Vaginal stenosis (cervical/endometrial brachytherapy): Radiation-induced vaginal fibrosis and stenosis are common late effects of pelvic brachytherapy in women, affecting sexual function and making future gynaecological examination difficult. Regular use of vaginal dilators commenced 4–6 weeks post-completion of brachytherapy is strongly recommended to minimise stenosis; topical oestrogen may provide symptomatic relief.
• Breast APBI toxicity: TARGIT-A IORT arm: 5-year Grade 3+ skin toxicity 0.5% vs. 2.1% (whole breast); grade 3+ breast effects 4.1% (TARGIT) vs. 4.9% (WBRT); similar cosmesis and quality of life. Interstitial APBI: local infection at catheter insertion sites (~3–5%); fat necrosis at the lumpectomy cavity (3–8%); telangiectasia. Balloon-based devices (MammoSite) carry higher infection and fat necrosis rates than multi-catheter interstitial in some series.
• Radiation safety (LDR permanent implants): Following permanent I-125 prostate seed implant, patients emit low levels of radiation for approximately 2 months. Public health precautions typically include: avoidance of sustained close contact (less than 15 cm for more than 2 hours) with pregnant women and young children for 2 months; seating at distance of greater than 15 cm from others during long journeys. Patients are advised to carry a radiation source card for travel through airport security.

Post-brachytherapy follow-up depends on the tumour site and technique used:

• Prostate LDR seed implant — PSA monitoring: PSA is measured at 3 and 6 months post-implant, then every 6 months for 2 years, and annually thereafter. A PSA nadir below 0.5 ng/mL is a favourable prognostic sign; the Phoenix definition of biochemical failure (PSA nadir + 2 ng/mL) is the standard endpoint. Post-implant dosimetry CT is performed at Day 30 to confirm adequate seed distribution; D90 ≥140 Gy (I-125) confirms quality implant. Post-brachytherapy PSA bounce (transient rise of ≥0.2 ng/mL) is common at 12–18 months (occurring in approximately 35–40% of patients) and should not be misinterpreted as failure.
• HDR prostate boost follow-up: Similar PSA monitoring schedule. Urinary toxicity assessment with IPSS/CTCAE at 3 months, 1, 2, and 5 years post-treatment. Erectile function (IIEF-5) and bowel function (EPIC) patient-reported outcomes at standard time points. MRI of the prostate is not routinely performed unless biochemical failure occurs.
• Cervical cancer follow-up: Clinical examination at 3-monthly intervals for 2 years, 6-monthly for years 3–5, then annually. MRI pelvis at 3 months post-completion of brachytherapy for response assessment (complete response vs. residual disease). PET-CT is used at 3–6 months where resources permit for systemic disease surveillance. Vaginal vault inspection at each follow-up; dilator use documented. CA-125 is not routinely used for surveillance.
• Endometrial cancer vaginal vault brachytherapy: Clinical and vaginal examination at 3 months, then annually or per standard oncology follow-up for the risk group. Routine surveillance imaging is not recommended for low-risk endometrial cancer in most guidelines (ESMO 2022).
• Breast APBI follow-up: Annual mammography post-APBI for life, clinical examination at 6 months and annually. Cosmesis assessment (Harris scale) at 1 and 3 years. The TARGIT-A trial demonstrated comparable rates of non-breast cancer mortality between IORT and WBRT groups, with IORT patients showing a significantly lower rate of non-cancer death (possible immunological abscopal benefit under investigation).

Brachytherapy costs vary by technique, centre, country, and whether it is used as monotherapy or as a component of multimodality treatment:

• Prostate LDR seed implant costs: In the United States, permanent prostate seed implant costs approximately USD 18,000–30,000 (professional and facility fees). This compares with USD 40,000–80,000 for robotic prostatectomy and USD 30,000–50,000 for EBRT/IMRT courses, making LDR brachytherapy one of the most cost-effective curative prostate cancer treatments. In India, prostate seed implant at specialist cancer hospitals costs approximately USD 3,000–7,000.
• HDR brachytherapy costs: HDR brachytherapy for cervical or prostate cancer involves capital equipment costs (remote afterloading machines cost USD 500,000–1,000,000) amortised over patient volumes. Per-course clinical costs for HDR cervical brachytherapy in the US range from USD 8,000–20,000; in India USD 1,500–5,000 at leading centres.
• APBI / IORT cost-effectiveness: Intraoperative radiotherapy (TARGIT/IORT) is performed in the same surgical session as lumpectomy, adding approximately USD 8,000–15,000 to the surgical costs in the US but eliminating 3–6 weeks of daily radiotherapy attendances, substantially reducing patient indirect costs (travel, accommodation, lost earnings). Interstitial APBI requires 4–5 day hospitalisation and catheter management expertise.
• Radioisotope source costs: I-125 prostate seeds cost approximately USD 25–50 per seed; a full implant uses 60–100 seeds. Ir-192 HDR sources require replacement every 3 months due to radioactive decay (half-life 73.8 days) — replacement sources cost approximately USD 15,000–25,000 per unit. These costs are included in the overall brachytherapy programme budget.
• Global access challenges: Despite its cost-effectiveness, brachytherapy is unavailable in many low- and middle-income countries (LMICs) — GEC-ESTRO surveys have documented that fewer than 20 countries have adequate brachytherapy access relative to estimated cancer burden. This is particularly concerning for cervical cancer, which predominantly affects women in LMICs and for which brachytherapy is an essential — not optional — component of curative treatment. The BRAVURA initiative (ESTRO-UICC) is working to expand brachytherapy capacity in Sub-Saharan Africa and South/Southeast Asia.
• Medical tourism: India, Thailand, and Turkey have established high-volume brachytherapy programmes at tertiary cancer centres with modern HDR remote afterloading equipment and GEC-ESTRO-compliant IGABT practice. International patients travelling for brachytherapy as part of a course of cervical cancer treatment should verify IGABT capability (MRI-guided, image-based planning per GEC-ESTRO guidelines) rather than older point-A-based conventional brachytherapy, which produces inferior outcomes.

The choice between brachytherapy and alternative treatments depends on cancer site, stage, risk stratification, institutional expertise, and patient preference:

• External beam radiotherapy (EBRT/IMRT/VMAT): For prostate cancer, dose-escalated IMRT (76–78 Gy in 38–39 fractions or hypofractionated 60 Gy in 20 fractions) achieves excellent disease control in low- and intermediate-risk prostate cancer. Comparison trials (RAVES, ASCENDE-RT) favour brachytherapy boost for intermediate- and high-risk disease due to superior biochemical control, but patient and centre factors influence the choice. For cervical cancer, the GEC-ESTRO evidence is unambiguous: omission of brachytherapy and substitution with EBRT boost (even IMRT/VMAT or SBRT) results in significantly inferior local control and higher morbidity — brachytherapy cannot be replaced by any external beam technique for cervical cancer.
• Stereotactic body radiotherapy (SBRT/SABR): SBRT delivers very high doses per fraction (typically 5–8 Gy) in 5–7 fractions to small, well-defined targets using multiple beams or arcs. For prostate cancer, SBRT (e.g., PACE-B trial: 36.25 Gy in 5 fractions) achieves equivalent 5-year biochemical control to conventional EBRT with acceptable toxicity and is increasingly offered as an alternative to LDR brachytherapy monotherapy in low-risk prostate cancer. However, no direct randomised comparison of SBRT versus LDR brachytherapy exists to date. Prostate SBRT toxicity profiles differ — SBRT produces more acute urinary symptoms; LDR produces more late urinary symptoms.
• Surgery (radical prostatectomy, hysterectomy): For prostate cancer, radical prostatectomy (open, laparoscopic, or robotic-assisted) provides equivalent long-term cancer control to radiotherapy/brachytherapy in localised disease (ProtecT trial: equivalent 10-year prostate cancer-specific mortality), with different side-effect profiles (earlier ED and stress incontinence vs. later urinary symptoms and rectal effects with radiotherapy). For cervical cancer, surgery (radical hysterectomy) is preferred for Stage IB1–IB2 disease where fertility preservation is a consideration or where radiation risk is high, but FIGO Stage IIA2 and above are treated with definitive chemoradiation + brachytherapy.
• Active surveillance / watchful waiting: For very low-risk prostate cancer (Gleason Grade Group 1, PSA density less than 0.15 ng/mL/cc, fewer than 3 positive biopsy cores) in men aged over 65–70 years, active surveillance avoids all treatment toxicity with equivalent prostate cancer-specific mortality outcomes at 10–15 years (ProtecT trial; Scandinavian SPCG-4). Brachytherapy or SBRT are appropriate alternatives when patients or their physicians prefer definitive treatment.
• Whole breast radiotherapy (WBRT) vs. APBI: For early-stage breast cancer following lumpectomy, conventional or hypofractionated whole breast radiotherapy (40 Gy in 15 fractions — UK START-B trial; or 26 Gy in 5 weekly fractions — UK FAST-Forward trial) remains the standard with the lowest absolute local recurrence rates. APBI/IORT is a validated option for "suitable" patients (ASTRO consensus criteria), offering equivalent locoregional control in selected low-risk women with significantly reduced treatment burden.